Myrexis Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Salt Lake City UT United States (1991)
Status: Defunct (2012)

Organization Overview

First Clinical Trial
2002
NCT00045123
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AssureRx Health, Inc. | Myriad Genetic Laboratories, Inc. | Myriad Genetics | Myriad Genetics, Inc. | Myriad Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Alzheimer Disease (Phase 3)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Dementia (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Glioblastoma (Phase 2)

HIV Infections (Phase 2)

Hypersensitivity (Phase 3)

Infections (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 28